PT-141 peptide for women is FDA-approved as Vyleesi for low sexual desire. Learn how it works, typical dosing, side effects, and safety considerations.
PT-141 (bremelanotide) is a synthetic peptide that the FDA approved in 2019 for premenopausal women with hypoactive sexual desire disorder (HSDD); it is sold under the brand name Vyleesi. It is given as an as-needed subcutaneous injection rather than a daily pill, and it works on brain signaling pathways instead of hormones or blood flow. It is not a cure for low desire and it does not address desire loss caused by relationship problems or medication side effects.
What Is PT-141 and How Does It Work?
PT-141 is a modified form of melanotan II, a peptide originally studied in the 1990s for tanning effects. During those studies, participants reported unexpected increases in sexual desire, which redirected research toward bremelanotide as a targeted treatment for low libido.
The drug binds to melanocortin receptors, mainly MC4R, in the central nervous system. Researchers believe this pathway influences dopamine signaling tied to desire and arousal, which is a different mechanism from hormones like estrogen or testosterone.
- Not a hormone: PT-141 does not raise or replace estrogen, testosterone, or progesterone.
- Not a daily drug: Unlike flibanserin, it is taken on demand, roughly 45 minutes before anticipated activity.
- Not a blood flow drug: It does not work like PDE5 inhibitors used for erectile dysfunction.
Does PT-141 Work for Women?
A frequent search question, does pt-141 work for women, has a more nuanced answer than most headlines suggest.
Two Phase 3 trials known as RECONNECT enrolled roughly 1,200 premenopausal women with HSDD. Compared with placebo, bremelanotide produced small but statistically significant improvements in sexual desire scores and reductions in distress related to low desire. Effects generally appeared within about 45 minutes and lasted for a few hours.
PT-141 does not work for every woman, and the average improvement measured in clinical trials was modest. Some participants reported a clear benefit while others noticed no meaningful change. Response appears to vary with dose, timing, and the underlying reason for low desire.
PT-141 Dosage for Women
The FDA-approved pt-141 dosage for women is 1.75 mg injected subcutaneously into the thigh or abdomen, taken about 45 minutes before anticipated sexual activity. It should not be used more than once in a 24-hour period or more than eight times per month.
Lower doses may be recommended for severe kidney impairment or severe liver impairment. Bremelanotide is currently approved only for premenopausal women, so there is no established dosing for postmenopausal use.
Online pt-141 dosage calculator for women tools can produce a number, but they cannot account for your kidney function, medications, or blood pressure history. Any dose should be confirmed by a clinician who knows your medical background.
| Factor | Women (FDA-approved Vyleesi) | Men (off-label or research use) |
|---|---|---|
| Typical dose | 1.75 mg subcutaneous injection | 1.75 to 2 mg subcutaneous, not FDA-approved |
| Timing | About 45 minutes before activity | Reported anecdotally, not established |
| Maximum frequency | Once per 24 hours, no more than 8 doses per month | No approved limit |
| FDA status | Approved for premenopausal women with HSDD | Not approved for any use |
Injection vs. Nasal Spray
Compounded pt-141 peptide nasal spray for women is sold by some online vendors and telehealth-adjacent sellers, but it is not FDA-approved and its absorption varies from product to product. Earlier clinical trials did test a nasal formulation, yet the agency approved only the injectable auto-injector.
Because nasal sprays are compounded rather than manufactured to a single standard, the amount absorbed per dose can differ between vendors and even between batches. That variability makes consistent dosing difficult to predict.
| Form | FDA status | Dose consistency | Notes |
|---|---|---|---|
| Subcutaneous injection (Vyleesi) | Approved | Standardized 1.75 mg auto-injector | The only form studied in the trials that led to approval |
| Compounded nasal spray | Not approved | Wide variation between vendors | A nasal version was studied historically but is not commercially approved |
| Research-grade powder | Not approved | Unknown | Labeled "not for human consumption"; no sterility or purity guarantee |
Side Effects and Safety
Nausea is the most commonly reported side effect, affecting roughly 40% of participants in the clinical trials. Flushing, headache, vomiting, and injection-site reactions are also common, and most of these effects are temporary.
Bremelanotide causes a small, short-lived increase in blood pressure, so it is not recommended for people with uncontrolled hypertension or known cardiovascular disease. Drinking alcohol may worsen nausea, and the drug can interact with naltrexone and certain other medications.
Focal hyperpigmentation, darkening of the skin, gums, or breasts, has been reported with frequent use. PT-141 is a prescription medication, and it should only be used under the supervision of a healthcare professional.
Buying PT-141 Online
Legitimate bremelanotide is available only by prescription in the United States. Searches for pt-141 peptide for sale amazon price typically lead to research-grade powders or gray-market vials that are not verified for purity, sterility, or actual drug content.
Injecting an unsterile or mislabeled peptide carries real risks, including infection, allergic reaction, and dosing errors. Products sold as research chemicals are not intended for human use and should not be injected.
The Bottom Line
PT-141 is a legitimate, FDA-approved option for premenopausal women with hypoactive sexual desire disorder, but its benefits in trials were modest and not everyone responds. It requires a prescription, careful screening for cardiovascular risk factors, and realistic expectations about what it can and cannot do. Anyone weighing this treatment should discuss it with a healthcare professional rather than ordering peptides from an unregulated seller.
Frequently Asked Questions
Does PT-141 work for women?
Yes, but the effect is modest. Bremelanotide is FDA-approved for premenopausal women with hypoactive sexual desire disorder after two Phase 3 trials showed small but statistically significant gains in desire and reductions in related distress. Response varies widely, and some women notice no benefit at all.
What is the typical PT-141 dosage for women?
The approved dose is 1.75 mg injected subcutaneously into the thigh or abdomen about 45 minutes before anticipated activity. It should not be used more than once per 24 hours or more than eight times per month, and lower doses may be advised for severe kidney or liver impairment.
Can you buy PT-141 peptide online?
Bremelanotide is prescription-only in the United States, so most listings sold online are research-grade peptides labeled "not for human consumption." These products carry no guarantee of purity, sterility, or actual drug content, and injecting them poses real health risks. Talk to a healthcare professional about a prescription instead.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.